1. Home
  2. NUVL vs OSK Comparison

NUVL vs OSK Comparison

Compare NUVL & OSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.86

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo Oshkosh Corporation

OSK

Oshkosh Corporation

HOLD

Current Price

$146.55

Market Cap

9.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
OSK
Founded
2017
1917
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
9.8B
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
NUVL
OSK
Price
$123.86
$146.55
Analyst Decision
Strong Buy
Buy
Analyst Count
16
14
Target Price
$134.75
$166.79
AVG Volume (30 Days)
2.4M
613.8K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
1.55%
EPS Growth
N/A
N/A
EPS
N/A
1.14
Revenue
N/A
$7,705,500,000.00
Revenue This Year
N/A
$5.94
Revenue Next Year
$1,239.49
$7.19
P/E Ratio
N/A
$125.25
Revenue Growth
N/A
12.83
52 Week Low
$71.14
$116.77
52 Week High
$123.86
$180.49

Technical Indicators

Market Signals
Indicator
NUVL
OSK
Relative Strength Index (RSI) 67.02 56.82
Support Level $98.56 $145.98
Resistance Level N/A $158.14
Average True Range (ATR) 0.15 5.03
MACD -0.67 -0.34
Stochastic Oscillator 93.27 49.93

Price Performance

Historical Comparison
NUVL
OSK

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About OSK Oshkosh Corporation

Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (45% of revenue), Vocational (35%), and Transport (20%) on 2025 revenue of $10.4 billion.

Share on Social Networks: